Pasar al contenido principal

PAPEL DE LOS CANALOSOMAS KV1.5 Y KV4.3 EN LA FIBRILACION AURICULAR. BUSQUEDA DE NUEVAS DIANAS TERAPEUTICAS Y HERRAMIENTAS MOLECULARES

PID2022-137214OB-C21

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

KCNE4-dependent modulation of Kv1.3 pharmacology

  • Sastre, Daniel
  • Colomer-Molera, Magalí
  • Benito-Bueno, Ángela de
  • Valenzuela, Carmen
  • Fernández-Ballester, Gregorio
  • Felipe, Antonio
The voltage-dependent potassium channel Kv1.3 is a promising therapeutic target for the treatment of autoimmune and chronic inflammatory disorders. Kv1.3 blockers are effective in treating multiple sclerosis (fampridine) and psoriasis (dalazatide). However, most Kv1.3 pharmacological antagonists are not specific enough, triggering potential side effects and limiting their therapeutic use. Functional Kv are oligomeric complexes in which the presence of ancillary subunits shapes their function and pharmacology. In leukocytes, Kv1.3 associates with KCNE4, which reduces the surface abundance and enhances the inactivation of the channel. This mechanism exerts profound consequences on Kv1.3-related physiological responses. Because KCNE peptides alter the pharmacology of Kv channels, we studied the effects of KCNE4 on Kv1.3 pharmacology to gain insights into pharmacological approaches. To that end, we used margatoxin, which binds the channel pore from the extracellular space, and Psora-4, which blocks the channel from the intracellular side. While KCNE4 apparently did not alter the affinity of either margatoxin or Psora-4, it slowed the inhibition kinetics of the latter in a stoichiometry-dependent manner. The results suggested changes in the Kv1.3 architecture in the presence of KCNE4. The data indicated that while the outer part of the channel mouth remains unaffected, KCNE4 disturbs the intracellular architecture of the complex. Various leukocyte types expressing different Kv1.3/KCNE4 configurations participate in the immune response. Our data provide evidence that the presence of these variable architectures, which affect both the structure of the complex and their pharmacology, should be considered when developing putative therapeutic approaches., Supported by the Ministerio de Ciencia e Innovación (MICINN/AEI), Spain (PID2020-112647RB-I00 and PID2023-148085OB-I00 (to AF), PID2022-137214OB-C21 (to CV) and 10.13039/501100011033) and European Regional Development Fund (FEDER)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Routing of Kv7.1 to endoplasmic reticulum plasma membrane junctions

  • Serrano-Novillo, Clara
  • Estadella, Irene
  • Navarro-Pérez, María
  • Oliveras, Anna
  • Benito-Bueno, Ángela de
  • Socuéllamos, Paula G.
  • Bosch, Manel
  • Coronado, María José
  • Sastre, Daniel
  • Valenzuela, Carmen
  • Soeller, Christian
  • Felipe, Antonio
[Aim]]: The voltage-gated Kv7.1 channel, in association with the regulatory subunit KCNE1, contributes to the IKs current in the heart. However, both proteins travel to the plasma membrane using different routes. While KCNE1 follows a classical Golgi-mediated anterograde pathway, Kv7.1 is located in endoplasmic reticulum-plasma membrane junctions (ER-PMjs), where it associates with KCNE1 before being delivered to the plasma membrane., [Methods]: To characterize the channel routing to these spots we used a wide repertoire of methodologies, such as protein expression analysis (i.e. protein association and biotin labeling), confocal (i.e. immunocytochemistry, FRET, and FRAP), and dSTORM microscopy, transmission electron microscopy, proteomics, and electrophysiology., [Results]: We demonstrated that Kv7.1 targeted ER-PMjs regardless of the origin or architecture of these structures. Kv2.1, a neuronal channel that also contributes to a cardiac action potential, and JPHs, involved in cardiac dyads, increased the number of ER-PMjs in nonexcitable cells, driving and increasing the level of Kv7.1 at the cell surface. Both ER-PMj inducers influenced channel function and dynamics, suggesting that different protein structures are formed. Although exhibiting no physical interaction, Kv7.1 resided in more condensed clusters (ring-shaped) with Kv2.1 than with JPH4. Moreover, we found that VAMPs and AMIGO, which are Kv2.1 ancillary proteins also associated with Kv7.1. Specially, VAP B, showed higher interaction with the channel when ER-PMjs were stimulated by Kv2.1., [Conclusion]: Our results indicated that Kv7.1 may bind to different structures of ER-PMjs that are induced by different mechanisms. This variable architecture can differentially affect the fate of cardiac Kv7.1 channels., Supported by the Ministerio de Ciencia e Innovación (PID2020-112647RB-I00 and PID2023-148085OB-I00 to AF and PID2022-137214OB-C21 to CV) and AEI (10.13039/501100011033), Spain and European Regional Development Fund (FEDER)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Indole-3-carbinol is an inhibitor of KV1.3 potassium voltage-gated channel activity in chronic lymphocytic leukemia cells

  • Baena-Nuevo, M.
  • Vera-Zambrano, Alba
  • Martínez-Laperche, Carolina
  • Buño, Ismael
  • Muñoz-Calleja, Cecilia
  • Valenzuela, Carmen
  • Zapata, Juan M.
  • Pérez-Chacón, Gema
Potassium voltage-gated channels are attractive drug targets for cancer treatment. In this report, we show that KV1.3 current amplitude is greater in CLL cells from refractory patients compared to CLL cells from untreated patients, further supporting a role for Kv1.3 channel as a target for refractory CLL disease. Indole-3 carbinol (I3C) is a clinically tested natural product found in edible Brassica plants. Here we show that I3C inhibits KV1.3 currents in transfected HEK293 (43.9 ± 7.6 %; 50 μM I3C), Burkitt's lymphoma BL60.2 (52.2 ± 5.2 %; 10 μM) and chronic lymphocytic leukemia (CLL) (57.7 % ± 5.2; 10 μM) cells. I3C inhibition was concentration-dependent in HEK293 (IC50 = 54 μM; nH = 3.2), BL60.2 (IC50 = 1.06 μM; nH = 0.53) and CLL (IC50 = 5.2 μM; nH = 0.95) cells, and the effect on KV1.3 was produced in a voltage-, time- and use-dependent manner, consistent with an open state blockade mechanism. I3C also inhibited KV11.1 currents, but failed to inhibit other KV channels and Kca3.1. Interestingly I3C did not induce mitochondrial depolarization of CLL cells, suggesting that I3C only targets plasma, but not mitochondria, Kv1.3 channels. I3C and derivatives 6-methyl-I3C and 3,3′-diindolylmethane, but no other indoles, that we previously showed induced apoptosis in Burkitt's and CLL cells, also efficiently inhibited KV1.3 currents. However, I3C-mediated KV1.3 currents inhibition was observed in CLL cells irrespective of their sensitivity to I3C-induced cell death, thus indicating that plasma membrane KV1.3 inhibition is not sufficient to induce CLL cell death., This study was supported by projects PID2019-110405RB-I00 and PID2022-136909OB-I00 (to JMZ), PID2019-104366RB-C21 and PID2022-137214OB-C21 (to CV), all funded by MCIN/AEI/10.13039/501100011033 and ERDF, EU. This study was also supported by Grant CB/11/00222 funded by Instituto de Salud Carlos III CIBERCV (to CV) and by 2023AEP049 funded by CSIC (to CV). It was also supported by S2022/BMD-7223 (to CV) and P2022/BMD-7225 (to JMZ) funded by Consortium in Biomedicine of Comunidad de Madrid., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Identification of a new selective ligand for targeting neuronal KV4.3/KChIP3 over cardiac KV4.3/KChIP2 channels

  • Socuellamos, Paula G.
  • Viedma-Barba, Carmen
  • de Benito-Bueno, Angela
  • Bonache de Marcos, María Ángeles
  • Ropero, Maria
  • Diez, Sara
  • Elizalde, Pablo
  • Marín-Olivero, Irene
  • Redondo-Moya, Maria
  • Naranjo, Jose Ramon
  • Gonzalez-Vera, Juan A.
  • Orte, Angel
  • Perez-Lara, Angel
  • Martín-Martínez, Mercedes
  • Valenzuela, Carmen
  • Gutiérrez-Rodríguez, Marta
The present study aimed to discover novel KChIP ligands as pharmacological tools for modulating the KV4.3/KChIP channels. A multidisciplinary approach, combining medicinal chemistry and electrophysiology studies, led to the successfully identification of a novel KV4.3/KChIP modulator (IQM-22110). Its design was guided by the previous knowledge of the (phenylacetamido)benzoic acid moiety as suitable scaffold, along with virtual screening of a focused chemical library that suggested improved KChIP3 binding upon incorporation of an additional aromatic ring. IQM-22110 was selected for synthesis and identified as a potent KChIP3 ligand. Its electrophysiological effects on KV4.3/KChIP3 currents indicate that IQM-22110 binds to a high affinity site in KV4.3/KChIP3 channels that it is not present in KV4.3/KChIP2 or KV4.3. To the best of our knowledge, here we describe the first KChIP3 ligand that selectively modulates KV4.3/KChIP3 versus KV4.3/KChIP2 and KV4.3 channels at nanomolar concentration. Since KChIP2 is predominantly expressed in cardiac tissue, this selectivity may enable the development of KV4.3/KChIP3-targeted therapeutics with reduced risk of cardiac side effects. Computational and site-directed mutagenesis studies allowed the identification of IQM-22110's binding site on KChIP3. Knowledge gained from structural and functional studies with this novel KChIP3 ligand could establish the basis for drug discovery programs fostering treatments for diseases in which KV4.3/KChIPs channels are involved., This work has been funded by grants: PID2022-137214OB-C21 (to CV) and PID2022-137214OB-C22 (to MG-R) funded by MCIN/AEI/h ttps://doi.org/10.13039/501100011033 and by “ERDF A way of mak ing Europe”; PID2023-148243OB-I00 AEI/https://doi.org/10.13039/ 501100011033 (to AO); Grant CB/11/00222 funded by Instituto de Salud Carlos III CIBERCV (to C.V.); CSIC grants 202580E109 (to MMM and MG-R) and 2023AEP049 (to CV); P. G. Socuéllamos was funded by FPU17/02731 granted by Spanish Minister of Science and Innovation. C. Viedma-Barba holds a FPI Predoctoral contracts subsidized by Spanish Minister of Science and Innovation (PRE2020-093542) granted by MCIN/AEI/https://doi.org/10.13039/501100011033 and “ESF Invest ing in your future”. A. de Benito-Bueno holds a FPI grant BES- 2017–080184. M. Redondo holds a FPI Contract subsidized by Spanish Minister of Science and Innovation (PREP2022-000706). A.P.-L. ac knowledges funding by a Ramon y Cajal grant (RYC2018-023837-I) and Max Planck Society through the funding of a Max Planck Partner Group on “Regulation of the SNARE zippering by complexins and synapto tagmins” at the University of Granada. We thank Centro de Supercomputaciónn de Galicia (CESGA) and Centro Técnico de Informática, CTI-CSIC for computer time at FinisTerrae III and DRAGO, respectively., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Lgi3-4 proteins modulate the KV1.5 channelosome and are potential therapeutic targets for atrial fibrillation

  • Socuéllamos, Paula G.
  • Macías, Álvaro
  • Benito-Bueno, Ángela de
  • Cruz, Francisco M.
  • Redondo-Moya, María
  • Coronado, María José
  • Ramil, Elvira
  • Rosado, Silvia
  • Rios-Rosado, Elsa Carolina
  • Valencia-Avezuela, María
  • Andrés-Delgado, Laura
  • Blázquez, José Antonio
  • Forteza-Gil, Alberto
  • Gutiérrez-Rodríguez, Marta
  • Jalife, José
  • Valenzuela, Carmen
We investigated the role of Lgi3-4 proteins in cardiac electrophysiology, with a specific focus on IKur, and their potential contribution to the pathophysiology of atrial fibrillation (AF)., Supported by Grants PID2019-104366RB-C21 (to C.V.), PID2019-104366RB-C22 (to M.G-R.), PID2022-137214OB-C21 (to C.V.); PID2022-137214OB-C22 (to M.G-R.) funded by MCIN/ AEI/10.13039/501100011033; Grant CB/11/00222 funded by Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (to C.V.); Grant S2022/BMD-7223 by Comunidad Autónoma de Madrid (CAM) (to C.V.); Grant FPU17/ 02731 (to P.G.S.); Grant BES-2017-080184 (to A.d.B.-B.); funded by Ministerio de Ciencia e Innovación. Supported also by National Heart, Lung and Blood Institute, NIH, grant number R01HL163943; La Caixa Banking Foundation project code HR18-00304 (LCF/PR/HR19/52160013); grants PI-FIS-2020 # PI20/01220 and PI-FIS-2023 # PI23/01039 from Instituto de Salud Carlos III (ISCIII) and co-funded by Fondo Europeo de Desarrollo Regional (FEDER), and by The European Union, respectively; grant PID2020-116935RB-I00 and BFU2016-75144-R funded by MCIN/AEI/10.13039/501100011033; Fundación La Marató de TV3 (736/C/2020) ‘amb el suport de la Fundació La Marató de TV3’; CIBERCV (CB16/11/00458; CB/11/00222 to CV); European Union’s Horizon 2020 grant agreement GA-965286; and Program S2022/BMD7229-CM ARCADIA-CM funded by Comunidad de Madrid (to JJ)., Peer reviewed